Spectral Medical Inc. Announces Closing of Second Tranche of $14.0 Million Convertible Note Private Placement
TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“ Spectral ” or the “ Company ”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“ PMX ”), is pleased to announce the closing of the second and final tranche of …
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


